ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib (IM) is the first successful molecular drug specifically targeting the aberrantly expressed BCR-ABL oncoprotein in CML cells, improving the estimated 8-year survival rate to ~88%32.